NCT02603029

Brief Summary

Objective of the study is to determine the influence of the cream with Silver fir wood (Abies alba) extract (Belinal) on the skin parameters and functions in comparison to the placebo cream. 10 healthy female subjects will use the test cream on one half and placebo cream on the other half of the face and of the gluteal part twice a day for 12 weeks. Various face skin parameters will be evaluated before the cream use (the baseline), after 6 and after 12 weeks of the cream use. To evaluate the photoprotective potential of Belinal the minimal erythema dose (MED) will be determined before (the baseline) and after 12 weeks of the cream use at the gluteal area.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2015

Shorter than P25 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

November 10, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 11, 2015

Completed
Last Updated

March 8, 2016

Status Verified

November 1, 2015

Enrollment Period

4 months

First QC Date

November 10, 2015

Last Update Submit

March 7, 2016

Conditions

Keywords

skin rejuvenationanti-ageing effectsminimal erythema dosedermis structurephysiological skin conditionwrinkling

Outcome Measures

Primary Outcomes (2)

  • Improvement of photoprotective function of the skin

    Minimal erythema dose (MED) of the skin will be determined. Skin on the gluteal part of the body will be exposed to 10 different doses of UVB light and 24 hours after exposure MED will be determined. Higher MED indicates better photoprotective function of the skin.

    up to 12 weeks of the supplementation

  • Improvement of the dermis structure

    Ultrasound (US) images of the dermis will be taken and intensity of the dermis determined. Higher intensity of the dermis US images indicates improvement of the collagen and elastin network.

    up to 12 weeks of Belinal cream use

Secondary Outcomes (6)

  • Reduction of the area of the periorbital facial wrinkles

    6 and 12 weeks of Belinal cream use

  • Reduction of the volume of the periorbital facial wrinkles

    6 and 12 weeks of Belinal cream use

  • Reduction of trans-epidermal water loss

    6 and 12 weeks of Belinal cream use

  • Improved skin hydration

    6 and 12 weeks of Belinal cream use

  • Improved skin elasticity

    6 and 12 weeks of Belinal cream use

  • +1 more secondary outcomes

Study Arms (2)

Placebo cream

PLACEBO COMPARATOR

Cream with 0% Silver fir wood extract (Belinal)

Other: Placebo cream

Belinal cream

ACTIVE COMPARATOR

Cream with 2% Silver fir wood extract (Belinal)

Other: Belinal cream

Interventions

Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.

Placebo cream

Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.

Belinal cream

Eligibility Criteria

Age45 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Signs of skin aging (mimic wrinkles/ fine lines/ poor skin tone/ photoaged skin),
  • Phototype II and III.

You may not qualify if:

  • Allergy to ingredients of tested products
  • Diagnosed diabetes
  • Thyroid disease
  • Inflammatory dermatoses
  • Regular use of dietary supplements 6 months or less before start of the study,
  • Invasive rejuvenation treatments (botox injections, hyaluronic acid fillers, needle rollers, needle mesotherapy, etc.) 6 months or less prior to start of the study,
  • Non-invasive rejuvenation treatments (radiofrequency, electrotherapy, ultrasound therapy, no-needle mesotherapy, etc.) 3 months or less prior to start of the study,
  • Regular, at least 14 day use of anti-aging cosmetic products containing peptides/ polyphenols/ stem cells extracts/ vitamins in high concentration/ AHAs/ BHAs/ vitamin A or its derivatives) three months or less prior to start of the study,
  • Gluteal hyperpigmentation,
  • Expected sunbathing (also in solariums) within the study period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Janko Zmitek, PhD

    VIST - Faculty of Applied Sciences

    STUDY CHAIR
  • Katja Zmitek, PhD

    VIST - Faculty of Applied Sciences

    STUDY DIRECTOR
  • Nataša Tavčar, BSc

    VIST - Faculty of Applied Sciences

    PRINCIPAL INVESTIGATOR
  • Tina Pogačnik, BSc

    VIST - Faculty of Applied Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 10, 2015

First Posted

November 11, 2015

Study Start

March 1, 2015

Primary Completion

July 1, 2015

Study Completion

July 1, 2015

Last Updated

March 8, 2016

Record last verified: 2015-11